Hardman research5 Nov 2023 15:48
“The large equipment and service providers, such as Illumina, LabCorp, Roche and Quest, have not been included in the table, as their activities in liquid biopsies and/or specialist tests are very small within their groups' diverse operations. Where these companies come into play is in M&A. Smaller companies tend to take most of the risk in developing novel tests, but are approached once the technology is substantially de-risked and there is evidence of commercial success. These large players have the financial muscle and operational resources to commercialise the tests on a worldwide basis.“
A key milestone was getting a billion dollar market cap partner like Bio-Techne. Another box ticked recently.